Conference Call with Indoco Remedies Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q3FY25 results Revenue of Indoco Remedies is at Rs 3,649 million, as against Rs 4,484 million, Q3FY24. EBIDTA to net sales for the quarter is at Rs 201 million, compared to Rs 653 million, Q3FY24. Aditi Panandikar, Managing Director, Indoco Remedies, said: “Domestic Formulation Business continued to contribute in revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.” Result PDF
Pharmaceuticals company Indoco Remedies announced Q2FY25 results Revenues: Rs 3,946 million, as against Rs 4,652 million, Q2FY24. EBIDTA: is 13.4 % at Rs 529 million, compared to 15.6% at Rs 724 million, Q2FY24 Profit After Tax: 3.2 % at Rs 128 million, compared to 7.1% at Rs 331 million, Q2FY24. Aditi Panandikar, Managing Director, Indoco Remedies said: “While a good performance by our Domestic Formulation business helped grow revenues, supply constraints have impacted the performance of the International Formulation business. Some of the sites supplying to US and Europe are under structured shutdowns to increase efficiency.” Result PDF